Multicenter trans-Atlantic experience with fenestrated-branched endovascular aortic repair of chronic post-dissection thoracoabdominal aortic aneurysms
Standard
Multicenter trans-Atlantic experience with fenestrated-branched endovascular aortic repair of chronic post-dissection thoracoabdominal aortic aneurysms. / Abdelhalim, Mohamed A; Tenorio, Emanuel R; Oderich, Gustavo S; Haulon, Stephan; Warren, Gasper; Adam, Donald; Claridge, Martin; Butt, Talha; Abisi, Said; Dias, Nuno V; Kölbel, Tilo; Gallitto, Enrico; Gargiulo, Mauro; Gkoutzios, Panos; Panuccio, Giuseppe; Kuzniar, Marek; Mani, Kevin; Mees, Barend M; Schurink, Geert W; Sonesson, Björn; Spath, Paolo; Wanhainen, Anders; Schanzer, Andres; Beck, Adam W; Schneider, Darren B; Timaran, Carlos H; Eagleton, Matthew; Farber, Mark A; Modarai, Bijan; International Multicenter Aortic Research Group.
In: J VASC SURG, Vol. 78, No. 4, 10.2023, p. 854-862.e1.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Multicenter trans-Atlantic experience with fenestrated-branched endovascular aortic repair of chronic post-dissection thoracoabdominal aortic aneurysms
AU - Abdelhalim, Mohamed A
AU - Tenorio, Emanuel R
AU - Oderich, Gustavo S
AU - Haulon, Stephan
AU - Warren, Gasper
AU - Adam, Donald
AU - Claridge, Martin
AU - Butt, Talha
AU - Abisi, Said
AU - Dias, Nuno V
AU - Kölbel, Tilo
AU - Gallitto, Enrico
AU - Gargiulo, Mauro
AU - Gkoutzios, Panos
AU - Panuccio, Giuseppe
AU - Kuzniar, Marek
AU - Mani, Kevin
AU - Mees, Barend M
AU - Schurink, Geert W
AU - Sonesson, Björn
AU - Spath, Paolo
AU - Wanhainen, Anders
AU - Schanzer, Andres
AU - Beck, Adam W
AU - Schneider, Darren B
AU - Timaran, Carlos H
AU - Eagleton, Matthew
AU - Farber, Mark A
AU - Modarai, Bijan
AU - International Multicenter Aortic Research Group
N1 - Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2023/10
Y1 - 2023/10
N2 - OBJECTIVE: This multicenter international study aimed to describe outcomes of fenestrated-branched endovascular aortic repairs (FB-EVAR) in a cohort of patients treated for chronic post-dissection thoracoabdominal aortic aneurysms (PD-TAAAs).METHODS: We reviewed the clinical data of all consecutive patients treated by FB-EVAR for repair of extent I to III PD-TAAAs in 16 centers from the United States and Europe (2008-2021). Data were extracted from institutional prospectively maintained databases and electronic patient records. All patients received off-the-shelf or patient-specific manufactured fenestrated-branched stent grafts. Endpoints were any cause mortality and major adverse events at 30 days, technical success, target artery (TA) patency, freedom from TA instability, minor (endovascular with <12 Fr sheath) and major (open or ≥12 Fr sheath) secondary interventions, patient survival, and freedom from aortic-related mortality (ARM).RESULTS: A total of 246 patients (76% male; median age, 67 years [interquartile range, 61-73 years]) were treated for extent I (7%), extent II (55%), and extent III (35%) PD-TAAAs by FB-EVAR. The median aneurysm diameter was 65 mm (interquartile range, 59-73 mm). Eighteen patients (7%) were octogenarians, 212 (86%) were American Society of Anesthesiologists class ≥3, and 21 (9%) presented with contained ruptured or symptomatic aneurysms. There were 917 renal-mesenteric vessels targeted by 581 fenestrations (63%) and 336 directional branches (37%), with a mean of 3.7 vessels per patient. Technical success was 96%. Mortality and rate of major adverse events at 30 days was 3% and 28%, including disabling complications such as new onset dialysis in 1%, major stroke in 1%, and permanent paraplegia in 2%. Mean follow-up was 24 months. Kaplan-Meier (KM) estimated patient survival at 3 and 5 years was 79% ± 6% and 65% ± 10%. KM estimated freedom from ARM was 95% ± 3% and 93% ± 5% at the same intervals. Unplanned secondary interventions were needed in 94 patients (38%), including minor procedures in 64 (25%) and major procedures in 30 (12%). There was one conversion to open surgical repair (<1%). KM estimated freedom from any secondary intervention was 44% ± 9% at 5 years. KM estimated primary and secondary TA patency were 93% ± 2% and 96% ± 1% at 5 years, respectively.CONCLUSIONS: FB-EVAR for chronic PD-TAAAs was associated with high technical success and a low rate of mortality (3%) and disabling complications at 30 days. Although the procedure is effective in the prevention of ARM, patient survival was low at 5 years (65%), likely due to the significant comorbidities in this cohort of patients. Freedom from secondary interventions at 5 years was 44%, although most procedures were minor. The significant rate of reinterventions highlights the need for continued patient surveillance.
AB - OBJECTIVE: This multicenter international study aimed to describe outcomes of fenestrated-branched endovascular aortic repairs (FB-EVAR) in a cohort of patients treated for chronic post-dissection thoracoabdominal aortic aneurysms (PD-TAAAs).METHODS: We reviewed the clinical data of all consecutive patients treated by FB-EVAR for repair of extent I to III PD-TAAAs in 16 centers from the United States and Europe (2008-2021). Data were extracted from institutional prospectively maintained databases and electronic patient records. All patients received off-the-shelf or patient-specific manufactured fenestrated-branched stent grafts. Endpoints were any cause mortality and major adverse events at 30 days, technical success, target artery (TA) patency, freedom from TA instability, minor (endovascular with <12 Fr sheath) and major (open or ≥12 Fr sheath) secondary interventions, patient survival, and freedom from aortic-related mortality (ARM).RESULTS: A total of 246 patients (76% male; median age, 67 years [interquartile range, 61-73 years]) were treated for extent I (7%), extent II (55%), and extent III (35%) PD-TAAAs by FB-EVAR. The median aneurysm diameter was 65 mm (interquartile range, 59-73 mm). Eighteen patients (7%) were octogenarians, 212 (86%) were American Society of Anesthesiologists class ≥3, and 21 (9%) presented with contained ruptured or symptomatic aneurysms. There were 917 renal-mesenteric vessels targeted by 581 fenestrations (63%) and 336 directional branches (37%), with a mean of 3.7 vessels per patient. Technical success was 96%. Mortality and rate of major adverse events at 30 days was 3% and 28%, including disabling complications such as new onset dialysis in 1%, major stroke in 1%, and permanent paraplegia in 2%. Mean follow-up was 24 months. Kaplan-Meier (KM) estimated patient survival at 3 and 5 years was 79% ± 6% and 65% ± 10%. KM estimated freedom from ARM was 95% ± 3% and 93% ± 5% at the same intervals. Unplanned secondary interventions were needed in 94 patients (38%), including minor procedures in 64 (25%) and major procedures in 30 (12%). There was one conversion to open surgical repair (<1%). KM estimated freedom from any secondary intervention was 44% ± 9% at 5 years. KM estimated primary and secondary TA patency were 93% ± 2% and 96% ± 1% at 5 years, respectively.CONCLUSIONS: FB-EVAR for chronic PD-TAAAs was associated with high technical success and a low rate of mortality (3%) and disabling complications at 30 days. Although the procedure is effective in the prevention of ARM, patient survival was low at 5 years (65%), likely due to the significant comorbidities in this cohort of patients. Freedom from secondary interventions at 5 years was 44%, although most procedures were minor. The significant rate of reinterventions highlights the need for continued patient surveillance.
KW - Aged
KW - Aged, 80 and over
KW - Female
KW - Humans
KW - Male
KW - Aortic Aneurysm, Abdominal/surgery
KW - Aortic Aneurysm, Thoracic/diagnostic imaging
KW - Aortic Aneurysm, Thoracoabdominal
KW - Blood Vessel Prosthesis/adverse effects
KW - Blood Vessel Prosthesis Implantation/adverse effects
KW - Endovascular Aneurysm Repair
KW - Endovascular Procedures/adverse effects
KW - Postoperative Complications
KW - Retrospective Studies
KW - Risk Factors
KW - Stents/adverse effects
KW - Treatment Outcome
U2 - 10.1016/j.jvs.2023.05.053
DO - 10.1016/j.jvs.2023.05.053
M3 - SCORING: Journal article
C2 - 37321524
VL - 78
SP - 854-862.e1
JO - J VASC SURG
JF - J VASC SURG
SN - 0741-5214
IS - 4
ER -